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Abstract
Background: Cell-free circulating DNA (cfDNA) is becoming a useful biopsy for noninvasive diagnosis of diseases.
Microbial sequences in plasma cfDNA may provide important information to improve prognosis and treatment. We
have developed a stringent method to identify microbial species via microbial cfDNA in the blood plasma of early-
onset breast cancer (EOBC) patients and healthy females. Empirically, microbe-originated sequence reads were
identified by mapping non-human PE reads in cfDNA libraries to microbial databases. Those mapped concordantly
to unique microbial species were assembled into contigs, which were subsequently aligned to the same databases.
Microbial species uniquely aligned were identified and compared across all individuals on MCRPM (Microbial CfDNA
Reads Per Million quality PE reads) basis.
Results: The predominant microbial cfDNAs in all plasma samples examined are originated from bacteria and these
bacteria were limited to only a few genera. Among those, Acinetobacter johnsonii XBB1 and low levels of
Mycobacterium spp. were commonly found in all healthy females, but also present in an EOBC patient.
Compared to those in healthy counterparts, bacterial species in EOBC patients are more diverse and more likely
to present at high levels. Among these three EOBC patients tested, a patient who has record high titer (2,724
MCRPM) of Pseudomonas mendocina together with 8.82 MCRPM of Pannonibacter phragmitetus has passed away;
another patient infected by multiple Sphingomonas species remains alive; while the third patient who has similar
microbial species (Acinetobacter johnsonii XBB1) commonly seen in normal controls is having a normal life.
Conclusions: Our preliminary data on the profiles of microbial cfDNA sequences suggested that it may have
some prognostic value in cancer patients. Validation in larger number of patients is warranted.
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Background
It is recently established that human blood contains cell-
free circulating DNA (cfDNA) resulted from apoptosis
and necrosis of normal and diseased human cells or
inhabited microbes [1]. Microbial genomic DNA can be
detected in plasma [2, 3], and the level of bacterial
sequences in cfDNA was found to be higher for diseased
and immunocompromised individuals than healthy
counterparts [4]. A number of studies have also indi-
cated that a low level of pleomorphic bacteria may
inhabit normal blood circulation [5–7], and bacteria
were also found in tumor tissues [8]. Data have also
shown that these microbes may regulate a broad range
of host physiological activities including metabolism,
inflammation, immunity and hematopoiesis, which may
in turn influence tumorigenesis and/or cancer develop-
ment [9]. These data suggest that microbiota may play a
key role to orchestrate cancer therapy and many more
cancer-associated microbes need to be identified.
It was estimated that 15–20% of human cancers
were caused by viral infections [10, 11]. The best-
known and best-studied carcinogenic microbes are
viruses. These include hepatitis B (HBV) and C
(HCV) viruses, human papillomavirus (HPV), human
T-cell leukemia virus and Epstein-Barr virus (EBV)
[12–16]. The discoveries of viral roles in tumorigen-
esis were facilitated by the fact that viruses are abso-
lute parasites and that viral genomes are generally
smaller and with fewer genes compared to bacterial
and fungal genomes. Although reports have shown
the presence of microbes in human breast cancer
tissues and lateral gene transfer of microbial genetic
sequences into the human genome, especially in
cancer tissues [17, 18]. Bacteria and fungi have com-
plex genomes and their interactions with hosts are
more intricate than that of viruses, making it more
difficult to justify their roles in tumorigenesis [18].
With the robust speed and yield of next-generation se-
quencing (NGS) [19], in combination with the noninva-
siveness and easy accessibility of liquid biopsies and the
availability of microbial genome databases, NGS-based
cfDNA sequencing is a powerful approach for studying
microbiota in body fluids. Recently, Grumaz and col-
leagues have demonstrated that NGS-coupled microbial
cfDNA analysis is strongly correlated with the results of
blood cultures [3]. Besides the Gram-negative bacteria
which exactly matched the results from corresponding
blood culturing, they also found microbial species show-
ing false negative in blood culture, indicating the super-
iority of the approach. Their work represents a proof-of-
concept pioneer work for direct detection of bacterial spe-
cies using plasma cfDNA.
Here, we present another NGS-based approach which is
able to identify microbes of a broad range. Our method
relies on a stringent mapping/alignment procedure for
specific association of microbial cfDNA sequences with
potential pathogens and rare microbial species which may
present in cancer patients and/or healthy individuals.
Empirically, paired-end (PE) reads unmappable to hg19
were collected and mapped to microbial databases
composed of bacterial, fungal and viral/phage genomes.
Those mapped concordantly to unique microbial species
were assembled into contigs, which were subsequently
used to BLAST the same microbial databases. The micro-
bial species aligned uniquely by contigs were considered
as the real hits. Microbes associated with each person
were portrayed with their relative microbial cfDNA levels
on a MCRPM (Microbial CfDNA Reads Per Million
quality PE reads) basis.
In this study, we identified microbial species in both
healthy and diseased females. One of the most striking
features is that the microbial inhabitants in breast cancer
patients are not only much more diverse than that of
normal females, but also can be tightly correlated to the
health conditions of the patients. Taken together, this
investigation indicates that NGS-based microbial cfDNA




Genomic sequences of bacteria, fungi and viruses were
downloaded from NCBI (April 6, 2017). Plasmids were
subsequently removed. The database contain 9,336, 913
and 9,050 genomes of bacteria, fungi and viruses/phages,
respectively (Table 1).
Library statistics
Five plasma DNA libraries including BBC (normal), EJC
(normal), BC0145 (EOBC), BC0190 (EOBC) and
CGBC025 (EOBC) were sequenced by Illumina HiSeq X
Ten to produce at least 384 million PE reads per library
(eq. ~ 38-fold coverage) (Table 2). Mapping against
human genome assembly hg19 resulted in mappable
ratios of 94.62%, 96.79%, 92.13%, 95.99% and 95.16% (eq.
Table 1 Microbial databases employed in the study
Bacteria Fungi Viruses
#Contigs 39,434 20 0
#Scaffold 36,076 170 3
#Chromosome 978 38 22
#Complete genome 6,711 7 7,175
#Subtotal 83,199 235 7,200
#Species 7,689 45 7,197
#Sequences 15,849 913 9,050
Total #, after plasmid sequences excluded 9,336 913 9,050
RefSeq genome: April 6, 2017
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to 5.38%, 3.21%, 7.87%, 4.01% and 4.84% of unmappable
ratios) for BBC, EJC, BC0145, BC0190 and CGBC025 li-
braries, respectively.
Most of the microbial cfDNA sequences were originated
from bacteria, instead of fungi or viruses/phages
Non-human PE reads (i.e., reads unmappable to hg19) were
mapped against the microbial databases. 0.08% - 4.85% (per
library) were found to be originated from bacteria, 0.00% -
0.01% from fungi, and 0.00% - 0.16% from viruses/phages
(Table 3, upper part). PE reads uniquely and concordantly
mapped to single species were then used to build contigs.
When contigs were aligned to the same microbial data-
bases, numbers of contigs aligned to bacteria were also sig-
nificantly higher than that aligned to either fungi or
viruses/phages for all libraries (Table 3, lower part).
Most bacterial cfDNA in healthy females are derived from
Acinetobacter spp., while high titers of bacterial cfDNA in
EOBC patients are derived from Pseudomonas or
Sphingomonas spp.
To compare the levels (or titers) of microbial cfDNA
fragments between individuals, the constituent sequence
reads of all contigs were summed up for each microbe
Table 2 Library statistics
Library BBC (normal) EJC (normal) BC0145 (EOBC) BC0190 (EOBC) CGBC025 (EOBC)
Raw PE reads 384,623,309 420,790,943 392,322,204 434,928,103 628,712,403
Quality PE reads 371,837,085 388,551,037 375,255,962 426,187,686 579,192,276
Normalization factor 372 389 375 426 579
hg19-mapped reads (%) 351,841,885 (94.62%) 376,097,300 (96.79%) 345,714,693 (92.13%) 409,083,110 (95.99%) 551,181,421 (95.16%)
hg19-unmappable PE reads (%) 19,995,200 (5.38%) 12,453,737 (3.21%) 29,541,269 (7.87%) 17,104,576 (4.01%) 28,010,855 (4.84%)
Table 3 Statistics of contigs and alignment
BBC EJC BC0145 BC0190 CGBC025
hg19-unmapped PE reads 19,995,200 12,453,737 29,541,269 17,104,576 28,010,855
Bacteria Mapped PE reads (%) 15,504 (0.08%) 31,653 (0.25%) 1,432,423 (4.85%) 50,310 (0.29%) 45,858 (0.16%)
Fungi Mapped PE reads (%) 451 (0.00%) 456 (0.00%) 590 (0.00%) 1,153 (0.01%) 996 (0.00%)
Viruses/Phages Mapped PE reads (%) 1,367 (0.01%) 677 (0.01%) 1,528 (0.01%) 26,749 (0.16%) 1,267 (0.00%)
Bacteria #Contigs 894 1,495 7,971 2,609 2,588
Max contig length 900 2,287 16,248 2,035 3,911
Min contig length 64 64 64 64 64
Median contig length 211 227 231 214 220
N50 215 266 1,616 219 237
#contigs w/ size ≥250 bp (%) 80 (9.0%) 558 (37.3%) 3,602 (45.2%) 333 (12.8%) 748 (28.9%)
#aligned contigs (also see Table 4) 54 381 2,456 225 451
Fungi #contigs 44 38 215 92 78
Max contig length 315 235 352 427 262
Min contig length 65 64 64 64 64
Median contig length 71 84 71 84 73.5
N50 99 192 78 192 127
#contigs w/ size ≥250 bp (%) 2 (4.6%) 0 (0.0%) 3 (1.4%) 3 (3.3%) 1 (1.3%)
#aligned contigs 2 0 0 2 1
Viruses/ phages #Contigs 75 62 287 155 72
Max contig length 655 546 336 695 274
Min contig length 64 64 64 64 64
Median contig length 68 84 70 73 74
N50 194 210 85 189 126
#contigs w/ size ≥250 bp (%) 9 (12.0%) 7 (11.3%) 10 (3.5%) 13 (8.4%) 1 (1.4%)
#aligned contigs 7 5 2 10 0
Huang et al. BMC Medical Genomics 2018, 11(Suppl 1):16 Page 35 of 95
and normalized on per-million basis (see Normalization
in Methods section). This strategy is able to reflect the
relative levels for the cfDNA fragment compositions in
the blood, because each read was supposed to be
resulted from a cfDNA fragment.
Alignment with contigs maximizes the accuracy of
microbial species identification, while read-level
normalization aims to achieve the best approximation
of relative titers for microbial species identified. Micro-
bial species mapped with single contigs were also
recorded because the number of constituent reads may
vary significantly and can be very high for long contigs.
Notice that each read represents a cfDNA fragment
either in the original plasma sample or produced by
PCR amplification. To minimize the impact of nonspe-
cific alignment, bacterial species with < 0.1 MCRMP
were removed from the list.
Bacterial species identified are significantly different
between healthy and diseased individuals (except
BC0190) (Table 4). As indicated by non-parametric
Mann-Whitney-Wilcoxon test, bacterial species found
between normal and diseased individuals are different
(p-value 0.020). Healthy females tend to harbor
Acinetobacter species, especially Acinetobacter johnsonii
XBB1, although the level may fluctuate (ranging between
0.27–6.00 MCRPM). Mycobacterium spp. and Ralstonia
mannitolilytica were also present in healthy females
(and BC0190 as well), but less significant. On the other
hand, EOBC patients tend to harbor more diverse bac-
terial species, presumably influenced by secondary infec-
tion. The highest titer (2742.72 MCRPM) was found to
be Pseudomonas mendocina ymp in patient BC0145,
while the second highest titer (13.64 MCRPM) was
Sphingomonas melonis in patient CGBC025. Patient
BC0145, who was diagnosed with bilateral breast cancer
and passed away a year after surgery in 2007 (see Plasma
cfDNA preparation in Methods section), was also
infected by other Pseudomonas spp. (e.g., P. alcaliphila
of 2.84 MCRPM and P. aeruginosa of 0.89 MCRPM) and
Pannonibacter phragmitetus (8.82 MCRPM). In contrast
to patients BC0145 and CGBC025 but similar to normal
females, patient BC0190 had Acinetobacter johnsonii
XBB1 as the major bacterial inhabitant. She had surgery
in February of 2007 and since then has been living a
healthy life.
Acinetobacter johnsonii (Gram-negative (G-)) is a ubi-
quitous bacterium commonly found in human and fish
[20–22]. However, it is becoming an emerging threat to
human health [23]. A. johnsonii XBB1 was first isolated
from a hospital in Chengdu City, China. Both Mycobac-
teria and Ralstonia mannitolilytica are also ubiquitous
in nature. R. mannitolilytica (G-), which was ever
named as Pseudomonas thomasii, Pseudmonas pickettii
or Ralstonia pickettii, is a soil bacterium. In 1989, this
bacterium caused a nosocomial outbreak in Taiwan
through sodium chloride contamination [24]. Sphingo-
monas melonis was first isolated from melon. Strain
Sphingomonas melonis sp. nov. is becoming a common
pathogen in melon fruits [25]. This species was
detected in both healthy and diseased females and a
high titer (13.64 MCRPM) was observed in patient
CGBC025.
Most of the bacteria on the list (even Pseudomonas
spp.) are known as opportunistic bacterial pathogens.
For example, P. aeruginosa (G-) is a bacterium com-
monly found in skin of healthy people [26]. Both R.
mannitolilytica, P. aeruginosa are innocuous bacteria,
but can be acquired from hospital where antibiotics are
commonly used. Through constant challenge by novel
and multiple antibiotics, they might have become multi-
drug resistant through horizontal transfer.
Fungal viral and phage species
When aligned to fungal and viral/phage databases, PE
reads of all five libraries showed no significant hit for all
individuals, either healthy or diseased. Thus, for all these
categories, results are much less significant than that of
bacterial species.
Conclusions
As revealed by previous investigations, microbes may
inhabit a number of human tissues which are technically
inaccessible for direct analysis. Fortunately, their
genomic sequences are released into blood circulation
and are thus become available for consecutive experi-
mentation for diagnostic or prognostic purposes. As
such, NGS-based cfDNA sequencing has emerged to be
one of the most suitable choices.
Here, we empirically demonstrate the feasibilities of
using NGS-based cfDNA sequencing for direct detection
of microbial species in human body. The feasibility is
made possible by NGS, the noninvasiveness and easy ac-
cessibility of plasma cfDNA samples, and a stringent
protocol for mapping and alignment.
The process is guarded by multiple layers of strin-
gency. Firstly, it started only with PE reads which map
concordantly to unique microbial genomes; both dis-
cordant hits and single-end hits were excluded in this
step, although single-end matches may be included dur-
ing contig assembly. Secondly, since microbes share sig-
nificant degree of sequence similarity, contigs were built
and used to align to the same microbial genome assem-
blies for better accuracy. Thirdly, contig-level alignment
was reinforced with stringent parameters. Fourthly, only
those microbial species “uniquely” aligned by contigs
were considered as real hits. Moreover, microbial spp.
with less than 0.1 MCRPM were excluded.
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Table 4 Bacterial species identified




Total no. of associated
PE reads
Total no. of associated
SE reads




Acinetobacter johnsonii XBB1 17 5,428 69 30 99 0.27
Bacillus cereus 2 708 6 35 41 0.11
Mycobacterium sp. 4 2,124 73 70 143 0.38
Ralstonia mannitolilytica 4 1,227 31 12 43 0.12
EJC ctl (sum/389)
Acinetobacter haemolyticus 12 4,345 59 30 89 0.23
Acinetobacter johnsonii XBB1 231 99,403 1,719 616 2,335 6.00
Acinetobacter junii 4 1,948 30 7 37 0.10
Acinetobacter lwoffii 17 6,186 87 31 118 0.30
Acinetobacter schindleri 4 1,770 43 16 59 0.15
Bacillus cereus 4 1,314 31 51 82 0.21
Corynebacterium pseudotuberculosis 2 588 2 48 50 0.13
Methylobacterium populi 18 5,102 54 18 72 0.19
Mycobacterium abscessus 4 2,238 53 14 67 0.17
Mycobacterium avium 8 2,751 30 15 45 0.12
Mycobacterium sp. 8 2,620 36 63 99 0.25
Mycoplasma mycoides 1 276 17 28 45 0.12
Porphyrobacter sp. 7 2,478 20 34 54 0.14
Ralstonia mannitolilytica 8 2,899 37 40 77 0.20
Sphingomonas sp. 11 3,533 27 28 55 0.14
BC 0145 (sum/375)
Pannonibacter phragmitetus 714 230,779 1,999 1,309 3,308 8.82
Pseudomonas aeruginosa 2 1,824 254 78 332 0.89
Pseudomonas alcaliphila 6 5,093 896 170 1,066 2.84
Pseudomonas mendocina ymp 1,675 2,678,493 918,733 109,787 1,028,520 2,742.72
Pseudomonas sp. 3 1,195 41 36 77 0.21
Pseudomonas stutzeri 3 1,717 220 21 241 0.64
Rhizobium sp. 34 12,418 144 65 209 0.56
BC 0190 (sum/426)
Acinetobacter baumannii 2 1,078 29 17 46 0.11
Acinetobacter johnsonii XBB1 71 24,930 366 168 534 1.25
Bacillus cereus 4 1,172 24 76 100 0.23
Methylobacterium populi 38 10,970 123 72 195 0.46
Mycobacterium abscessus 5 2,599 67 28 95 0.22
Mycobacterium sp. 7 2,432 52 88 140 0.33
Porphyrobacter sp. 6 2,195 38 31 69 0.16
Ralstonia mannitolilytica 7 2,370 19 53 72 0.17
Sphingomonas sp. 17 5,030 63 44 107 0.25
CGBC 025 (sum/579)
Acinetobacter baumannii 24 6,818 118 48 166 0.29
Bradyrhizobium sp. 7 2,059 41 16 57 0.10
Enterobacter cloacae 8 3,140 108 33 141 0.24
Sphingobium japonicum 8 5,088 262 43 305 0.53
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Although only five samples were analyzed, this
study reveals a number of interesting phenomena: 1)
microbial cfDNA can also be detected in the blood
plasma of healthy individuals; 2) bacteria constitute
the major microbial species in human body; 3) these
bacteria belong to only a limited number of genera
and species, no matter for healthy or diseased individ-
uals; 4) most microbial species in healthy human bod-
ies show only low levels of cfDNA; 5) Acinetobacter
(esp., A. johnsonii XBB1) cfDNA is ubiquitous for
healthy individuals, but it may also present in EOBC
patient with near normal heath conditions; 6) on the
other hand, Pseudomonas and Sphingomonas cfDNA
can be found in the plasma of breast cancer patients with
severe symptoms; 7) microbial spp. in breast cancer pa-
tients tend to be more diverse compared to that in healthy
counterparts.
Pseudomonas species are well known opportunistic
bacteria commonly found on the surface of human body.
It is thus not surprising to detect Pseudomonas in can-
cer patients with symptoms severe enough to comprom-
ise the immune system. On the other hand, the presence
of Sphingomonas melonis in a cancer patient is some-
what surprising. In natural environment, this bacterium
is known to cause brown spots on yellow Spanish
melons. Its pathogenicity upon human was first de-
scribed only 15 years ago [25]. Its quick spreading is a
warning sign to human communities.
For cancer or other diseases resulted from viruses
living constantly in human body (e.g., HPV and HSV
which cause cervical cancer and herpes respectively),
the presence of corresponding viral cfDNA sequences
in plasma are expected. However, the viral cfDNA
titer is expected to fluctuate with its proliferation
status, with relatively higher titer during active stage
and lower titer during dormant stage. For breast
cancer, no clear correlation with viral pathogens has
ever been unambiguously demonstrated. This partially
explains why no significant viral cfDNA were detected
among these EOBC patients.
Furthermore, the microbial species detected in EOBC
patients may not be responsible for the tumorigenesis of
the disease, because, as influenced by health conditions
as well as environmental factors, the composition of
microbial species in human body can be very dynamic
and the cfDNA sequences of the causative agents may
no longer present or may present only at an insignificant
level when the disease is eventually established. How-
ever, our results indicate a correlation between disease
status and the composition of microbial cfDNA in
plasma, and suggest the feasibility of using NGS-based
microbial cfDNA sequencing for personalized treatment
of diseases.
Although this study allows us to extrapolate certain
interesting phenomena from microbial cfDNA in
plasma, the capacity of our approach is limited by
sample size. We intend to survey large number of
healthy and diseased individuals in the future, including
patients with different types of cancer and/or different
cancer stages. Besides cancer, it would also be interesting
to expand the approach to other diseases, especially
chronic diseases such as Type I and Type II diabetes.
Through analysis of microbial cfDNA in plasma, we
should be able to gain further insight into the role
played by microbial inhabitants during the progression
of a disease. Knowledge of this kind should be able




Detailed information about the EOBC patients: 1)
Patient BC0145 (ER-, PR+ and HER-2+) was diag-
nosed at age 39.5 to have infiltrating ductal carcin-
oma at grade III in both breasts, had surgery on
August 22, 2006 and passed away on September 01,
2007 (about 1 year after surgery). 2) Patient BC0190
(ER+, PR+ and HER-2+) was diagnosed at age 25.1 to
have infiltrating ductal carcinoma at grade III, had
her surgery on February 16, 2007 and was reported
to remain healthy in April of 2017. 3) Patient
CGBC025 (ER+, PR+ and HER-2+) was diagnosed at
age 34.8 to have invasive ductal carcinoma at grade
II, had her surgery on August 28, 2015 and remains
alive and healthy.
Blood samples were taken from EOBC patients
BC0145, BC0190 and CGBC025 at age 39.5, 25.1 and
34.8, respectively, and normal blood samples were
prepared from healthy females BBC and EJC, both less
Table 4 Bacterial species identified (Continued)




Total no. of associated
PE reads
Total no. of associated
SE reads
Sum of PE and SE
reads
MCRPM
Sphingomonas melonis 336 157,346 5,397 2,503 7,900 13.64
Sphingomonas panacis 4 1,261 36 30 66 0.11
Sphingomonas sp. 51 21,410 720 271 991 1.71
Only microbial species with MCRPM ≥ 0.1 are listed. Those with MCRPM ≥ 1 are listed in bold.
Ctl control; MCRPM, microbial cfDNA per million quality PE reads; sp. (same as spp.), species with unspecified species name
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than 30 years old. All plasma cfDNA samples were
isolated from blood using Quick-cfDNA Serum and
Plasma Kit (Zymo Research, D4076) following manufac-
turer’s instructions.
Preparation of microbial reference databases
Microbial reference databases were downloaded from
NCBI reference genome database (ftp://ftp.ncbi.nlm.-
nih.gov/genomes/refseq/, April 6, 2017). For each cat-
egory, only “Complete Genome” and “Chromosome”
from assembly_summary.txt according guide line from
NCBI web site (https://www.ncbi.nlm.nih.gov/genome/
doc/ftpfaq/#allcomplete) were used in mapping/align-
ment. The final reference databases contain 9,336
bacterial sequences, 9,050 viral sequences, and 913
fungal sequences (Table 1).
Sequencing and sequence processing
Sequences were determined by 150 × 150 PE sequencing
(30×) using Illumina HiSeq X Ten (Macrogen Corp).
Illumina sequencing adapter was trimmed by cuta-
dapt. Both base quality and read quality were checked
after contaminant reads were removed. PRINseq [27]
was employed for base quality checking following the
sequential steps: removal of low quality bases from
both 5′- and 3′-ends, removal of reads having ≥ 3
ambiguous (N) bases, and removal of reads with read
length < 30 bp. NGS QC Toolkit [28] was then used
to select high quality reads each of which has base
score ≥ 20 in ≥ 70% of the contained bases. A general-
ized workflow for data analysis is shown in Fig. 1.
Mapping of PE reads against microbial databases
Quality PE reads were mapped to UCSC hg19 human
genome assembly using bowtie2 under default param-
eters (maximum insert size defined as 800 bp). The
unmapped PE reads were then used to map against
bacterial, viral and fungal databases separately with
bowtie2 under multiple hit output option (parameters:
–end-to-end –no-mixed –no-discordant –k 2). The
option “-k 2” defines the maximum number of hits as
2 (species) per PE read [29]. Since there exists a high
degree of similarity among microbial sequences, we
chose only PE reads that hit concordantly to a unique
microbial species for contig assembly.
Contig assembly and alignment for microbial species
identification
Contigs were assembled with SOAPdenovo using
Kmer 63 and then used to BLAST (BLASTN) against
the same microbial databases with the following cri-
teria: i) sequence identity ≥ 95%; ii) contig length ≥
250 bp; and iii) contig aligned ratio (aligned length/
contig length) = 100% (i.e., full range aligned). Strains
belonging to the same genus/species were merged
and number of contigs and total contig length were
summed up accordingly.
Normalization
Normalization is essential for intra- and inter-library
comparison of microbial cfDNA level. It is calculated
based on the number of reads, instead of the num-
ber of contigs associated with each microbial species.
Notice that, the numbers of reads per contig may
vary, and only the total read count, which correlates
the total number of cfDNA fragments in plasma, is
able to reflect the level of cfDNA fragments in
plasma.
Thus, the numbers of sequence reads associated
with all contigs that aligned to each species were
summed up and normalized on “per-million quality
reads” basis. This approach would not only reflect the
relative levels of microbial cfDNA fragments in the
original sample, but also allow us to weigh the
relative significance among microbial cfDNA across
all libraries.
Fig. 1 Workflow showing the stepwise procedure of sequence data
processing leading to the identification of microbes in the body
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Statistical analysis
To compare the amount of microbial cfDNA in plasma
between cancer patients and normal females, the average
value of titer in MCRPM for each microbial species was
calculated separately for normal females and diseased
patients. Then, the averages for all bacteria were com-
pared across these two groups using the non-parametric
Mann-Whitney-Wilcoxon test.
Abbreviations
cfDNA: Cell-free DNA; CTCs: Circulating tumor cells; EOBC: Early-onset breast
cancer; MCRPM: Microbial cfDNA reads per million quality PE reads;
NGS: Next-Generation Sequencing; PE: Paired-End
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